NCT05155098View on ClinicalTrials.gov

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis

Active, not recruitingOBSERVATIONAL
Enrollment

127

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis
Interventions
OTHER

secukinumab

Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.

Trial Locations (10)

10300

Novartis Investigative Site, Bangkok

10330

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

12120

Novartis Investigative Site, Muang

30000

Novartis Investigative Site, Muang

40000

Novartis Investigative Site, Muang

40002

Novartis Investigative Site, Khon Kaen

50200

Novartis Investigative Site, Chiang Mai

90110

Novartis Investigative Site, Songkhla

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY